Ranalozine proved also ability to cross the blood-brain barrier while tested in rats, which together with inhibition of persistent current in mutant NaV1.1 channels give rise for possible providing a new useful therapeutic strategy for SCN1A-associated epilepsy and some migraine syndroms [69]. The gene discussed is SCN1A; the disease is epilepsy.